Natera, Inc. (NTRA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). Investors who purchased Natera shares are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Natera and certain of its officers and/or directors have violated federal securities laws.


On January 1, 2022, the New York Times published an article that called into question the accuracy of certain of Natera’s prenatal tests, reporting, among other things, that positive test results are incorrect approximately 85 percent of the time and that patients who receive a positive result on such tests are instructed to pursue follow-up testing, which “can cost thousands of dollars, come with a small risk of miscarriage and can’t be performed until later in pregnancy.”  On this news, Natera’s stock price fell $2.26 per share, or 2.42%, to close at $91.13 per share on January 3, 2022.

Then, on January 14, 2022, the Campaign for Accountability filed a complaint letter with the Securities and Exchange Commission (“SEC”), alleging that Natera misled investors and failed to disclose the false positives from four of the five disorders screened by Panorama. The Campaign for Accountability complaint also alleged that Natera issued false and misleading reports about Panorama’s accuracy. Following this news, Natera stock dropped again, thereby damaging investors.


If you are aware of any facts relating to this investigation or purchased Natera shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.